FDA Cancels Proposed Rule On Clinical Trial Malfeasance
Executive Summary
US FDA has withdrawn a proposed rule that would have required sponsors to notify FDA if they became aware of data falsification during a clinical trial. Industry had been critical of the 2010 proposal.
You may also be interested in...
US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling
A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.
US FDA's data falsification rule raises industry concerns
The US medtech industry has expressed serious concerns about a new rule proposed by the FDA, which, if finalised, would require device sponsors to report to the agency about any individual who is suspected of falsifying data in studies involving human or animal subjects.
News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals
This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.